Court Approves Sale of CVS's Omnicare Unit to GenieRx
CVS sits 68% above its 52-week low of $58.35.
Summary
A U.S. bankruptcy court has approved the sale of CVS Health's Omnicare unit to GenieRx Holdings. This development follows Omnicare's bankruptcy filing in September to address litigation issues. While the financial terms of the deal were not disclosed, this court approval marks a significant step towards resolving the bankruptcy and divesting the long-term care pharmacy services provider. The transaction is expected to close later this year, pending regulatory approvals and customary conditions. Traders will monitor for further details on the financial impact of this divestiture on CVS Health.
At the time of this announcement, CVS was trading at $98.05 on NYSE in the Trade & Services sector, with a market capitalization of approximately $125.2B. The 52-week trading range was $58.35 to $98.22. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.